Eli Lilly expands GLP-1 medicines distribution with Mubadala Bio: Can LLY continue gains?

Traders Union
All News
Stocks
Eli Lilly jumps 3.33% to $1,313 today

Highlights

Eli Lilly formed a partnership with Mubadala Bio to localize packaging and logistics for GLP-1 medicines in Abu Dhabi, targeting improved distribution in the region.
Second-quarter revenue reached $23 billion, led by strong sales of Mounjaro at $9.94 billion and Zepbound at $4.93 billion.
Shares of Eli Lilly trade with bullish technical signals, and the price is expected to consolidate in the $1,282 to $1,345 range over the next 2 to 3 days.

Operational expansion and strong demand drive revenue and prescription growth

Eli Lilly’s newly announced collaboration with Mubadala Bio to localize packaging and logistics of its GLP-1 medicines in Abu Dhabi is expected to enhance the distribution and operational efficiency of the company’s diabetes treatments, potentially expanding product uptake in a new market. Alongside this, second-quarter results showed revenue reaching $23 billion, with strong contributions from Mounjaro ($9.94 billion) and Zepbound ($4.93 billion), according to Pharmexec, confirming robust demand for core therapies. Eli Lilly has also introduced its LillyDirect telehealth platform, enabling patients prescribed Zepbound to access home delivery, a move that may drive further prescription growth and streamline patient access.

Bullish momentum persists amid mixed oscillator signals and firm support

The price is currently above the MA-20 at $1,271 and the MA-50 at $1,243 on the hourly chart, and remains well above the daily MA-200 at $1,082. The Ichimoku Kijun is set at $1,275 and now acts as immediate support. MACD shows strong buy momentum, while ADX is neutral, suggesting trend strength is limited for now. RSI is at 54.16 (Buy), with Stochastic RSI in oversold territory, indicating potential for renewed upward momentum. CCI and the Awesome Oscillator are neutral, and Bull/Bear Power is overbought, pointing to prevailing buyer strength in intraday trading. The mixed oscillator readings hint at active market participation but do not yet confirm a clear continuation trend.

Consolidation expected as price approaches technical breakout levels

Looking ahead, the next 2–3 trading days are likely to see LLY trade in a range of $1,282 to $1,345, representing a typical volatility band relative to current levels. The primary scenario is for price consolidation within this zone. Should the price break above $1,345, a move to new highs is likely, while a drop below $1,282 may open the way for further downside movement.

Viktoras Karapetjanc, Senior Analyst at Traders Union, sees Eli Lilly’s recent operational partnership in Abu Dhabi as a decisive step for expanding regional presence. He believes strong realized revenue from diabetes therapies and the launch of telehealth services confirm robust demand trends. Fundamental momentum remains solid with the price holding above key support levels. "I expect continued strength in Eli Lilly as strategic moves and strong fundamentals attract buyers at these levels."

Earlier, analysts noted that Eli Lilly was experiencing strong upward momentum driven by robust demand, regulatory progress, and key partnerships. The current analysis strengthens that outlook, with improved operational efficiency and expanding global reach supporting the prevailing scenario of price consolidation unless a confirmed breakout above $1,345 emerges in the coming sessions.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.